Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Cardiff Oncology Stock Price, Quotes and Forecasts | NASDAQ:CRDF | Benzinga

Q: What sector and industry does Cardiff Oncology (CRDF) operate in?

Cardiff Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Explore Cardiff Oncology stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for CRDF.

Open	$2.88
Close	$3.05
Volume / Avg.	1.28M / 1.22M
Day Range	$2.87 - $3.08
52 Wk Range	2.01 - 5.64
Market Cap	$202.90M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	48
Short Interest	22.7%
Days to Cover	13.29

Recent News

US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift'

Small businesses are entering the holiday season with newfound confidence and momentum, thanks to post-election policies and reduced inflation.

Piero Cingari

What's Going On With Cardiff Oncology Stock On Tuesday?

Cardiff Oncology's CRDF-004 trial shows promising onvansertib results in RAS-mutated mCRC patients, with higher tumor response rates and a strong safety profile.

Vandana Singh

Crude Oil Down Over 1%; Quoin Pharmaceuticals Shares Spike Higher

U.S. stocks traded lower toward the end of trading, with the S&P 500 edging lower on Monday. The Dow traded down 0.20% to 39,007.30 while the NASDAQ fell 0.18% to 16,245.77. The S&P 500 also fell, dropping, 0.01% to 5,137.05.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Nov 24

Dec 24

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$2.88
Close	$3.05
Volume / Avg.	1.28M / 1.22M
Day Range	$2.87 - $3.08
52 Wk Range	2.01 - 5.64
Market Cap	$202.90M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	48
Short Interest	22.7%
Days to Cover	13.29

About Cardiff Oncology Inc

Sector

Health Care

Industry

Biotechnology

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-va...

Got Questions? Ask

What are analysts' targets for CRDF?

What is CRDF's all-time high price?

What is CRDF's gross margin?

What is CRDF's operating cash flow?

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Cardiff Oncology (CRDF) stock?

You can purchase shares of Cardiff Oncology (NASDAQ:CRDF) through any online brokerage.

View our list of the best stock brokerages

Who are Cardiff Oncology (CRDF) competitors?

Other companies in Cardiff Oncology’s space includes: Voyager Therapeutics (NASDAQ:VYGR), Sangamo Therapeutics (NASDAQ:SGMO), Eledon Pharmaceuticals (NASDAQ:ELDN), Anika Therapeutics (NASDAQ:ANIK) and Genfit (NASDAQ:GNFT).

What is the forecast, or price target, for Cardiff Oncology (CRDF) stock?

Cardiff Oncology has a consensus price target of $10.80.

What is the current price for Cardiff Oncology (CRDF)?

The stock price for Cardiff Oncology (NASDAQ: CRDF) is $3.05 last updated April 22, 2025 at 4:00 PM EDT.

Does Cardiff Oncology (CRDF) pay a dividend?

There are no upcoming dividends for Cardiff Oncology.

When is Cardiff Oncology (NASDAQ:CRDF) reporting earnings?

Cardiff Oncology’s Q1 earnings are confirmed for Monday, May 5, 2025.

Is Cardiff Oncology (CRDF) going to split?

There is no upcoming split for Cardiff Oncology.

What sector and industry does Cardiff Oncology (CRDF) operate in?

Cardiff Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Cardiff Oncology Stock Price, Quotes and Forecasts

Cardiff Oncology (CRDF) Forecast